phosphogluconate dehydrogenase การใช้

• 6-Phosphogluconate dehydrogenase deficiency can be asymptomatic in many patients who are carriers.
• Recently, phosphogluconate dehydrogenase has been posited as a potential drug target for African sleeping sickness ( trypanosomiasis ).
• It is formed by 6-phosphogluconolactonase, and acted upon by phosphogluconate dehydrogenase to produce ribulose 5-phosphate.
• Structural differences between mammalian and trypanosome 6-phosphogluconate dehydrogenase have allowed for the development of selective inhibitors of the enzyme.
• The general structure, as well as several critical residues, on 6-phosphogluconate dehydrogenase appear to be well conserved over various species.
• The lack of synthesis of a specific protein on chromosome 1 has reduced a subject suffering from 6PGD deficiency from producing adequate amounts of the 6-Phosphogluconate dehydrogenase enzyme.
• Pentose Phosphate Pathway with a breakdown in the conversion of 6-Phosphogluconate dehydrogenase to Ribulose-5-phosphate due to a deficiency of 6-Phosphogluconate Dehydrogenase enzyme.
• Pentose Phosphate Pathway with a breakdown in the conversion of 6-Phosphogluconate dehydrogenase to Ribulose-5-phosphate due to a deficiency of 6-Phosphogluconate Dehydrogenase enzyme.
• Since NADPH is required by both thioredoxin reductase and glutathione reductase to reduce oxidized thioredoxin and glutathionine, 6-phosphogluconate dehydrogenase is believed to be involved in protecting cells from oxidative damage.
• 6-phosphogluconate dehydrogenase is involved in the production of ribulose 5-phosphate, which is used in nucleotide synthesis, and functions in the pentose phosphate pathway as the main generator of cellular NADPH.
• "Penicillium chrysogenum " has been used industrially to produce penicillin and xanthocillin X, to treat pulp mill waste, and to produce the enzymes polyamine oxidase, phosphogluconate dehydrogenase, and glucose oxidase.
• 6-phosphogluconate dehydrogenase ( 6PGD ) deficiency has similar symptoms and is often mistaken for G6PD deficiency, as the affected enzyme is within the same pathway, however these diseases are not linked and can be found within the same patient.
• "' 6-Phosphogluconate dehydrogenase deficiency "'( "'6PGD deficiency "'), or partial deficiency, is an autosomal hereditary disease characterized by abnormally low levels of 6-Phosphogluconate dehydrogenase ( 6PGD ), a metabolic enzyme involved in the Pentose phosphate pathway.
• "' 6-Phosphogluconate dehydrogenase deficiency "'( "'6PGD deficiency "'), or partial deficiency, is an autosomal hereditary disease characterized by abnormally low levels of 6-Phosphogluconate dehydrogenase ( 6PGD ), a metabolic enzyme involved in the Pentose phosphate pathway.
• Several studies have linked oxidative stress to diseases such as Alzheimer's disease, as well as cancer, These studies have found phosphogluconate dehydrogenase activity to be up-regulated, both in tumor cells and in relevant cortical regions of Alzheimer's patient brains, most likely as a compensatory reaction to highly oxidative environments.
• Based on null mutant experiments of 6-phosphogluconate dehydrogenase ( Gnd ) ( a key enzyme of the cyclic oxidation pathway ), and methenyl H4MPT cyclohydrolase ( CH ) ( participating in the direct oxidation of formaldehyde via H4MPT derivatives ), Chistoserdova et al . have found that Gnd null mutants were not obtained, but CH null mutants were obtained.